2-[4-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯基]-1,3,4-噁二唑 | 276694-19-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-[4-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯基]-1,3,4-噁二唑
• 英文名称: 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,3,4-oxadiazole
• 英文别名: 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3,4-oxadiazole
• CAS: 276694-19-0
• 化学式: C₁₄H₁₇BN₂O₃
• 分子量: 272.112
• InChiKey: YWMKIDKLUDAMTL-UHFFFAOYSA-N

物化性质

• 沸点：
  387.6±44.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.04
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  57.4
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

反应信息

• 作为反应物：
  描述：

  2,4,6-三氯嘧啶 、 2-[4-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯基]-1,3,4-噁二唑 在 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 10.0h， 以71%的产率得到
  参考文献：
  名称：

  화합물 및 이를 포함하는 유기 발광 소자

  摘要：

  本规范提供了化学式1的化合物以及包含它们的有机发光器件。

  公开号：

  KR20210004849A
• 作为产物：
  描述：

  4-氯苯甲酰肼 在 potassium acetate 、 palladium diacetate 、 氯化铵 、 三环己基膦 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 反应 12.0h， 生成 2-[4-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯基]-1,3,4-噁二唑
  参考文献：
  名称：

  화합물 및 이를 포함하는 유기 발광 소자

  摘要：

  本规范提供了化学式1的化合物以及包含它们的有机发光器件。

  公开号：

  KR20210004849A

文献信息

• Process for the preparation of paraoxadiazolyphenylboronic acids
  申请人：Clariant GmbH

  公开号：US06197967B1

  公开（公告）日：2001-03-06

  Compounds of the formula (I) are prepared by reacting a compound of the formula (V) with a compound of the formula (X) and hydrolyzing the product; or converting the compound of the formula (V) into the hydrazide, and cyclizing and hydrolyzing the latter to give the oxadiazole. para-Oxadiazolylphenylboronic acids are valuable precursors for active ingredients.

  通过将公式（V）的化合物与公式（X）的化合物反应并水解产物；或将公式（V）的化合物转化为肼酰肼，环化并水解后得到氧代唑。公式（I）的化合物由此制备而成。对于活性成分，对于对位-氧代唑基苯硼酸是有价值的前体。
• Kinase inhibitors useful for the treatment of proliferative diseases
  申请人：Flynn L. Daniel

  公开号：US20080114006A1

  公开（公告）日：2008-05-15

  The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferrably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

  本发明涉及一种新型激酶抑制剂和调节剂化合物，用于治疗各种疾病。更具体地说，本发明涉及这样的化合物、激酶/化合物加合物、治疗疾病的方法以及合成化合物的方法。优选地，这些化合物对Raf激酶及其疾病多态性的激酶活性调节是有用的。本发明的化合物在哺乳动物癌症，特别是人类癌症，包括但不限于恶性黑色素瘤、结肠直肠癌、卵巢癌、乳头状甲状腺癌、非小细胞肺癌和间皮瘤的治疗中发挥作用。本发明的化合物也在治疗类风湿性关节炎和视网膜病变，包括糖尿病性视网膜神经病变和黄斑变性方面发挥作用。
• Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
  申请人：Deciphera Pharmaceuticals, Inc.

  公开号：US08188113B2

  公开（公告）日：2012-05-29

  The present invention relates to novel dihydropyridopyrimidinyl, dihydronaphthyridinyl, and related compounds which are kinase inhibitors and modulator useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

  本发明涉及一种新型的二氢吡啶吡嗪基，二氢萘嗪基和相关化合物，这些化合物是激酶抑制剂和调节剂，可用于治疗各种疾病。更具体地说，本发明涉及这些化合物，激酶/化合物加合物，治疗疾病的方法以及合成这些化合物的方法。优选地，这些化合物对Raf激酶及其疾病多态体的激酶活性的调节具有用处。本发明的化合物在哺乳动物癌症治疗中，特别是人类癌症治疗中，包括但不限于恶性黑色素瘤、结肠直肠癌、卵巢癌、乳头状甲状腺癌、非小细胞肺癌和间皮瘤中具有用处。本发明的化合物在类风湿性关节炎和视网膜病变治疗中也具有用处，包括糖尿病性视网膜神经病变和黄斑变性。
• KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES
  申请人：Flynn Daniel L.

  公开号：US20120289540A1

  公开（公告）日：2012-11-15

  The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferrably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

  本发明涉及新型激酶抑制剂和调节剂化合物，可用于治疗各种疾病。更具体地说，本发明涉及这种化合物、激酶/化合物加合物、治疗疾病的方法以及化合物的合成方法。优选地，这些化合物可用于调节Raf激酶及其疾病多态性的激酶活性。本发明的化合物在哺乳动物癌症治疗中特别是人类癌症治疗中，包括但不限于恶性黑色素瘤、结直肠癌、卵巢癌、乳头状甲状腺癌、非小细胞肺癌和间皮瘤等方面有用。本发明的化合物还在类风湿性关节炎和视网膜病变，包括糖尿病视网膜神经病变和黄斑变性的治疗中有用。
• 一种HPK 1和/或LCK激酶调节剂、制备方法及其应用
  申请人：杭州医学院

  公开号：CN116162087A

  公开（公告）日：2023-05-26

  本发明公开了一种如式(I)的化合物及其制备方法和在药物制剂中的应用。如式(I)的化合物具有优良的HPK 1和/或LCK激酶抑制活性且能显著促进免疫相关的细胞因子释放，改善T细胞功能障碍，治疗因HPK 1和/或LCK激酶异常所引起的相关疾病。